Denmark-based diabetes device dev RSP Systems said today it raised approximately $7.6 million (EU €6.5 million) in a Series B round to support its non-invasive glucose monitor technology.
Funds raised in the round will help support clinical trials, pursuit of regulatory approval and eventual commercialization for its glucose monitoring technology.
The round was joined by a number of family offices and private investors, RSP Systems said, including BASF board chair Jürgen Hambrecht and RSP CEO Andreas Jenne.
“The Series B financing round builds on an exceptional year for RSP Systems where the company has significantly advanced its technology platform, as featured in an article recently published in Plos One,” CEO Andreas Jenne said in a press release.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.